APLS · Apellis Pharmaceuticals, Inc.
Market Cap
$5.25B
Shares
128.02M
Apellis Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Apellis Pharmaceuticals, Inc. (APLS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$14.38M
−$138.94M
'22 Q1
22-03-31
▲2519.9%
$16.32M
−$155.98M
'22 Q2
22-06-30
▲290.4%
$22.06M
−$191.27M
'22 Q3
22-09-30
▲211.8%
$44.85M
−$177.78M
'23 Q1
23-03-31
▲481.8%
$94.97M
−$122.04M
'23 Q2
23-07-31
▲400.5%
$110.40M
−$140.24M
'23 Q3
23-10-05
▲545.9%
$146.38M
−$88.58M
'23 Q4
24-01-08
▲284.3%
$172.32M
−$66.42M
'24 Q1
24-03-31
▲110.3%
$199.69M
−$37.66M
'24 Q2
24-06-30
▲78.3%
$196.83M
−$57.45M
'24 Q3
24-09-30
▲45.2%
$212.53M
−$36.35M
'24 Q4
25-01-13
▼3.2%
$166.80M
−$92.22M
'25 Q1
25-03-31
▼10.6%
$178.49M
−$42.15M
'25 Q2
25-06-30
▲133%
$458.58M
$215.72M
'25 Q3
25-09-30
LATEST
▼5.9%
$199.91M
−$58.95M
'25 Q4
26-01-12
Earnings call
FY25 · Q4
2026-01-12
Apellis Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Positive tone
SYFOVRE commercial performance in geographic atrophy
EMPAVELI launch in C3G and primary IC-MPGN
Prefilled syringe innovation for SYFOVRE
Revenue
$199.91M*
▼ 5.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Apellis Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Positive tone
EMPAVELI launch in C3G and primary IC-MPGN
SYFOVRE / Geographic Atrophy growth challenges
Financial outlook and guidance
Revenue
$458.58M
▲ 133% YoY Diluted EPS
$1.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Apellis Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Positive tone
SYFOVRE commercial performance in GA
EMPAVELI label expansion into C3G / IC-MPGN
Competitive landscape in GA
Revenue
$178.49M
▼ 10.6% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Apellis Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Balanced tone
EMPAVELI C3G/IC-MPGN launch
SYFOVRE revenue shortfall
SYFOVRE market leadership and demand
Revenue
$166.80M
▼ 3.2% YoY Diluted EPS
$-0.74
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Apellis Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
Empaveli / C3G and IC-MPGN launch
Geographic Atrophy market leadership
Quarterly headwinds (Q1 2025)
Revenue
$212.53M*
▲ 45.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Apellis Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Cautious tone
SYFOVRE commercial performance
EMPAVELI in C3G and IC-MPGN (VALIANT)
Gross-to-net adjustments
Revenue
$196.83M
▲ 78.3% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Apellis Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
SYFOVRE commercial performance and market leadership
EMPAVELI and pipeline expansion (VALIANT)
Competitive dynamics with Izervay
Revenue
$199.69M
▲ 110.3% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Apellis Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
SYFOVRE commercial growth
EMPAVELI commercial performance
Pipeline expansion (C3G/IC-MPGN)
Revenue
$172.32M
▲ 284.3% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Apellis Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
SYFOVRE commercial performance
EMPAVELI franchise in PNH
SYFOVRE safety / vasculitis
Revenue
$146.38M*
▲ 545.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-05
Apellis Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$110.40M
▲ 400.5% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-31
Apellis Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$94.97M
▲ 481.8% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Apellis Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$44.85M
▲ 211.8% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q3
2022-09-30
Apellis Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$22.06M
▲ 290.4% YoY Diluted EPS
$-1.75
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Apellis Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$16.32M
▲ 2519.9% YoY Diluted EPS
$-1.46
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Apellis Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$14.38M
Diluted EPS
$-1.42
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Apellis Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Apellis Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$5.65M
▲ 774.6% YoY Diluted EPS
$-2.28
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Apellis Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$623,000
Diluted EPS
$-2.72
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Apellis Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Apellis Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Diluted EPS
$0.93
Rev · 2q
Audio
Transcript
Slides
8-K10-K
Showing 1–20 of 20 earnings calls